Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia

CompletedOBSERVATIONAL
Enrollment

152

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2024

Conditions
AnemiaAnemia (Iron-Loading)Perioperative BleedingInfection PreventionReadmission, HospitalSurgical ComplicationLength of Hospital StayIron Deficiency Anemia TreatmentPrehabilitation
Interventions
DRUG

Ferric Carboxymaltose (FCM)

Patients in the intervention group underwent surgery from 2020 to end-2022 and were managed according to the surgery prehabilitation protocol. Once the surgeon has included the patient on the SWL, they were evaluated and followed up by the prehabilitation nurse (no more than 72 hours in the case of cancer patients) together with the study internist. The protocol at this preoperative stage consists of a comprehensive biopsychosocial assessment and an analysis of lab and nutritional parameters, which are optimized using targeted treatment. One of the lab parameters analyzed was Hb. Study patients with Hb \< 13 g/dL received 500 mg, 1000 mg, 1500 mg or 2000 mg FCM, depending on their levels of Hb, ferritin, transferrin saturation index, and weight. The lab test was repeated immediately before surgery or 30 days after administration of FCM in order to determine whether Hb levels had improved with FCM therapy

Trial Locations (1)

28981

Hospital Universitario Infanta Cristina, Parla

All Listed Sponsors
lead

Hospital Universitario Infanta Cristina

OTHER

NCT06948864 - Evaluate the Outcomes of Ferric Carboxymaltose in Patients With Perioperative Anemia | Biotech Hunter | Biotech Hunter